Characterization of the optimized nanoparticles (These values are means of a minimum of 5 batches). by Anjuman Arora (750291)

Subjects:

Mean-difference plots by country: Countries with decreased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with increased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

Mean-difference plots by country: Countries with no change in variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

“…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”

Rapamycin treatment significantly decreases induction of lytic KSHV proteins. by Lisa A. Nichols (357612)

Conditional <i>Aff4</i> knockout decreases fat mass in mice. by Yaqian Chen (1711576)

Mean change in incidence and diagnoses if testing rates decrease. by Richard T. Gray (282417)

The ratio of standard deviation to mean dose (SD/mean) decreases with neuronal dose. by Murat Alp (781371)

Rapamycin decreases Schwann cell markers, whereas statin induces Schwann cell markers. by Andrea Preitschopf (629851)

Quantitation of the decrease in viability of schistosomula caused by GSK343 treatment at different concentrations and incubation times. by Adriana S. A. Pereira (5900249)

UPLC-DAD profile (270 nm) of phytocannabinoids in the extracts separated in C18 column. by Bruno Musetti (9527085)

Subjects:

Removal of the A-B linker did not decrease PIP₂ affinity. <i>A.-</i> by Paloma Aivar (124885)

NaSal increased the excitability of 5-HTergic neurons, but decreased that of GABAergic neurons in the DRN of the ChR2 transgenic mouse. by Yan Jin (143500)

“…(D) Sample traces (left panel) and group data (right panel, paired Student’s <i>t</i>-test) showing that NaSal suppressed the firing of GABAergic neurons evoked by laser light (1 s, 5.5 mW, 473 nm). (E) Sample recordings from a GABAergic neuron showing that NaSal decreased voltage responses to a series of hyperpolarizing currents (-10 to -60 pA, -10 pA/step, duration: 500 ms). …”

Mean daily consultation counts. by Yael Rachamin (6161423)

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.</p>…”

CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. by Wanassa Beroual (5314028)